Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency

A. Grahnen, K. Kastrup, U. Heinrich, M. Gourmelen, M. A. Preece, M. A. Vaccarello, J. Guevara-Aguirre, Ronald (Ron) Rosenfeld, A. Sietnieks

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The pharmacokinetics of recombinant human insulin-like growth factor I (rhIGF-I) were studied in healthy volunteers and in patients with growth hormone receptor deficiency (GHRD; Laron syndrome). Following single subcutaneous injections of rhIGF-I, 40 and 80 μg/kg, to healthy volunteers, the peptide was absorbed slowly, with a maximum concentration reached after about 7 hours. Following daily multiple subcutaneous injections of rhIGF-I, 40 μg/kg, trough concentrations of IGF-I were increased by 277 ± 50 μg/l (mean ± SD) from baseline. IGF-I was thus characterized as a low-clearance peptide, with a clearance and half-life estimated at about 0.20 ml/minute/kg and 20 hours, respectively, in healthy volunteers. The volume of distribution was low, about 0.20-0.36 litres/kg, the bioavailability of subcutaneously administered rhIGF-I was 100%, and the rate of production of IGF-I was estimated to be about 50 μg/kg/day (3.5 mg/day). Patients with GHRD had low baseline IGF-I concentrations (30-50 μg/l) and a much more rapid turnover of IGF-I compared with that in healthy volunteers. The clearance and half-life of IGF-I were estimated to be about 0.60 ml/minute/kg and 6 hours, respectively. The volume of distribution was about the same as in healthy subjects. Due to the rapid turnover of IGF-I, trough IGF-I concentrations were increased to just above baseline during subcutaneous injections of 40 μg/kg once daily for 7 days. The maximum increase in IGF-I levels was 111 ± 12 μg/l and 150 ± 3 μg/l following daily subcutaneous injections of 40 x 1 and 40 x 2 μg/kg for 7 days, respectively.

Original languageEnglish (US)
Pages (from-to)9-13
Number of pages5
JournalActa Paediatrica, International Journal of Paediatrics, Supplement
Volume82
Issue number391
StatePublished - 1993
Externally publishedYes

Fingerprint

Laron Syndrome
Insulin-Like Growth Factor I
Healthy Volunteers
Pharmacokinetics
Subcutaneous Injections
Half-Life
Peptides

Keywords

  • growth hormone receptor deficiency
  • hypoglycaemia
  • insulin-like growth factor I
  • Laron syndrome
  • pharmacokinetics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. / Grahnen, A.; Kastrup, K.; Heinrich, U.; Gourmelen, M.; Preece, M. A.; Vaccarello, M. A.; Guevara-Aguirre, J.; Rosenfeld, Ronald (Ron); Sietnieks, A.

In: Acta Paediatrica, International Journal of Paediatrics, Supplement, Vol. 82, No. 391, 1993, p. 9-13.

Research output: Contribution to journalArticle

Grahnen, A, Kastrup, K, Heinrich, U, Gourmelen, M, Preece, MA, Vaccarello, MA, Guevara-Aguirre, J, Rosenfeld, RR & Sietnieks, A 1993, 'Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency', Acta Paediatrica, International Journal of Paediatrics, Supplement, vol. 82, no. 391, pp. 9-13.
Grahnen, A. ; Kastrup, K. ; Heinrich, U. ; Gourmelen, M. ; Preece, M. A. ; Vaccarello, M. A. ; Guevara-Aguirre, J. ; Rosenfeld, Ronald (Ron) ; Sietnieks, A. / Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. In: Acta Paediatrica, International Journal of Paediatrics, Supplement. 1993 ; Vol. 82, No. 391. pp. 9-13.
@article{6bd334e8a37047fbbed4fa42f6ef6b26,
title = "Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency",
abstract = "The pharmacokinetics of recombinant human insulin-like growth factor I (rhIGF-I) were studied in healthy volunteers and in patients with growth hormone receptor deficiency (GHRD; Laron syndrome). Following single subcutaneous injections of rhIGF-I, 40 and 80 μg/kg, to healthy volunteers, the peptide was absorbed slowly, with a maximum concentration reached after about 7 hours. Following daily multiple subcutaneous injections of rhIGF-I, 40 μg/kg, trough concentrations of IGF-I were increased by 277 ± 50 μg/l (mean ± SD) from baseline. IGF-I was thus characterized as a low-clearance peptide, with a clearance and half-life estimated at about 0.20 ml/minute/kg and 20 hours, respectively, in healthy volunteers. The volume of distribution was low, about 0.20-0.36 litres/kg, the bioavailability of subcutaneously administered rhIGF-I was 100{\%}, and the rate of production of IGF-I was estimated to be about 50 μg/kg/day (3.5 mg/day). Patients with GHRD had low baseline IGF-I concentrations (30-50 μg/l) and a much more rapid turnover of IGF-I compared with that in healthy volunteers. The clearance and half-life of IGF-I were estimated to be about 0.60 ml/minute/kg and 6 hours, respectively. The volume of distribution was about the same as in healthy subjects. Due to the rapid turnover of IGF-I, trough IGF-I concentrations were increased to just above baseline during subcutaneous injections of 40 μg/kg once daily for 7 days. The maximum increase in IGF-I levels was 111 ± 12 μg/l and 150 ± 3 μg/l following daily subcutaneous injections of 40 x 1 and 40 x 2 μg/kg for 7 days, respectively.",
keywords = "growth hormone receptor deficiency, hypoglycaemia, insulin-like growth factor I, Laron syndrome, pharmacokinetics",
author = "A. Grahnen and K. Kastrup and U. Heinrich and M. Gourmelen and Preece, {M. A.} and Vaccarello, {M. A.} and J. Guevara-Aguirre and Rosenfeld, {Ronald (Ron)} and A. Sietnieks",
year = "1993",
language = "English (US)",
volume = "82",
pages = "9--13",
journal = "Acta Paediatrica, International Journal of Paediatrics, Supplement",
issn = "0803-5326",
publisher = "Taylor and Francis Ltd.",
number = "391",

}

TY - JOUR

T1 - Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency

AU - Grahnen, A.

AU - Kastrup, K.

AU - Heinrich, U.

AU - Gourmelen, M.

AU - Preece, M. A.

AU - Vaccarello, M. A.

AU - Guevara-Aguirre, J.

AU - Rosenfeld, Ronald (Ron)

AU - Sietnieks, A.

PY - 1993

Y1 - 1993

N2 - The pharmacokinetics of recombinant human insulin-like growth factor I (rhIGF-I) were studied in healthy volunteers and in patients with growth hormone receptor deficiency (GHRD; Laron syndrome). Following single subcutaneous injections of rhIGF-I, 40 and 80 μg/kg, to healthy volunteers, the peptide was absorbed slowly, with a maximum concentration reached after about 7 hours. Following daily multiple subcutaneous injections of rhIGF-I, 40 μg/kg, trough concentrations of IGF-I were increased by 277 ± 50 μg/l (mean ± SD) from baseline. IGF-I was thus characterized as a low-clearance peptide, with a clearance and half-life estimated at about 0.20 ml/minute/kg and 20 hours, respectively, in healthy volunteers. The volume of distribution was low, about 0.20-0.36 litres/kg, the bioavailability of subcutaneously administered rhIGF-I was 100%, and the rate of production of IGF-I was estimated to be about 50 μg/kg/day (3.5 mg/day). Patients with GHRD had low baseline IGF-I concentrations (30-50 μg/l) and a much more rapid turnover of IGF-I compared with that in healthy volunteers. The clearance and half-life of IGF-I were estimated to be about 0.60 ml/minute/kg and 6 hours, respectively. The volume of distribution was about the same as in healthy subjects. Due to the rapid turnover of IGF-I, trough IGF-I concentrations were increased to just above baseline during subcutaneous injections of 40 μg/kg once daily for 7 days. The maximum increase in IGF-I levels was 111 ± 12 μg/l and 150 ± 3 μg/l following daily subcutaneous injections of 40 x 1 and 40 x 2 μg/kg for 7 days, respectively.

AB - The pharmacokinetics of recombinant human insulin-like growth factor I (rhIGF-I) were studied in healthy volunteers and in patients with growth hormone receptor deficiency (GHRD; Laron syndrome). Following single subcutaneous injections of rhIGF-I, 40 and 80 μg/kg, to healthy volunteers, the peptide was absorbed slowly, with a maximum concentration reached after about 7 hours. Following daily multiple subcutaneous injections of rhIGF-I, 40 μg/kg, trough concentrations of IGF-I were increased by 277 ± 50 μg/l (mean ± SD) from baseline. IGF-I was thus characterized as a low-clearance peptide, with a clearance and half-life estimated at about 0.20 ml/minute/kg and 20 hours, respectively, in healthy volunteers. The volume of distribution was low, about 0.20-0.36 litres/kg, the bioavailability of subcutaneously administered rhIGF-I was 100%, and the rate of production of IGF-I was estimated to be about 50 μg/kg/day (3.5 mg/day). Patients with GHRD had low baseline IGF-I concentrations (30-50 μg/l) and a much more rapid turnover of IGF-I compared with that in healthy volunteers. The clearance and half-life of IGF-I were estimated to be about 0.60 ml/minute/kg and 6 hours, respectively. The volume of distribution was about the same as in healthy subjects. Due to the rapid turnover of IGF-I, trough IGF-I concentrations were increased to just above baseline during subcutaneous injections of 40 μg/kg once daily for 7 days. The maximum increase in IGF-I levels was 111 ± 12 μg/l and 150 ± 3 μg/l following daily subcutaneous injections of 40 x 1 and 40 x 2 μg/kg for 7 days, respectively.

KW - growth hormone receptor deficiency

KW - hypoglycaemia

KW - insulin-like growth factor I

KW - Laron syndrome

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0027360090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027360090&partnerID=8YFLogxK

M3 - Article

C2 - 8219484

AN - SCOPUS:0027360090

VL - 82

SP - 9

EP - 13

JO - Acta Paediatrica, International Journal of Paediatrics, Supplement

JF - Acta Paediatrica, International Journal of Paediatrics, Supplement

SN - 0803-5326

IS - 391

ER -